SALVAT completes enrolment for Phase III study of acute otitis media drug

Spanish pharmaceutical group SALVAT has finished enrolling patients with acute otitis media (middle ear infection) in its Phase III study designed to assess the efficacy and safety of a new otic solution comprising ciprofloxacin and fluocinolone.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news